Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers